Venous Stents Market is expected to exceed the market valuation of more than US$ -- million by 2027 expanding at a reasonable CAGR of around --% during the forecast period (2021-2027). In the past few years, deep venous stenting has gained increased attention in treating acute or chronic post-thrombotic obstructions or iliac vein compression. Veins are larger, externally compressed, have lower flow and more scarred. New wall stents are entering the market, they usually need to go through vigorous testing before they can be approved. Two stents Venovo by Bard and Vici by Boston Scientific were approved by FDA in 2019.
Some of the characteristics and evidence about these venous stents are previewed in the report. Data for the Venovo stent was collected for 3 years on 170 patients and 5 years for Vici stent, again on 170 patients, before they got FDA approval for general public use. Other key players approved around the same time include Zilver Vena by Cook Medical, Abre by Medtronic, Optimed has developed four types of stents and Blueflow Venous Stent by Plus Medica GmbH.
Before the pandemic vascular disease treatments could be elective, urgent, and emergent in nature. Elective Procedures performed routinely also include venous stenting. Urgent and emergent cases combined with nonelective arterial disease comprise of approximately 30%-50% of vascular surgery practices. The timelines and efficacy of care was disrupted due to the pandemic. Physicians were under the dilemma of callig patients to hospital due to the potential Covid-19 exposure. Also, hospital were instructed by the governemnts to use their resources more for covid-related-admissions. Even the outpatient vascular services and office-based laboratories were severely affected mostly for elective venous treatments. In a global survey consucted by ng et al., vascular surgeons reported an 86.9% downscale or suspension of services due to the pandemic.
Based on technology, the venous stents market is bifurcated into illiac vein stent technology and wallstent technology. The wallstent segment was valued at US$ -- million in 2020 wallstents have been the most common stent type available since a very long time. More than 50% of the patients get wallstent in the US every year. Wallstent has excellent long-term patency with a good clinical outcome, however, wallstents are prone to migration and compression at the upper end of the stent and thus requires reinterventions. As per a report published in 2019 it was found that endovascular repair has a good success rate with very few complications. 75% of the cases are treated with stents as opposed to angioplasty alone. In many cases thrombectomy may also be necessary.
Based on application, the venous stents market is fragmented into legs, chest, abdomen, and others. The legs segment was valued at US$ -- million in 2020 and is likely to reach US$ -- million by 2027 growing at a CAGR of --% from 2021-2027. Key factors that made leg segment the frontrunner is the increasing prevalence of Deep Vein Thrombosis. An estimated 900,000 people get effected by DVT in the US each year. Additionally, about 33% of the people with cured DVT had a recurrence within 10 years.
Based on disease, the venous stents market is fragmented into chronic deep vein thrombosis, post thrombotic syndrome, and others. The chronic deep vein segment was valued at US$ -- million in 2020 and is likely to reach US$ -- million by 2027 growing at a CAGR of --% from 2021-2027. Key factor increasing the occurrence of chronic deep vein thrombosis is the increasing geriatric population. Age plays a major factor in this disease as the elderly are more likely to have DVT. In 2019, 9% of the world population was above 65 years of age.
Additionally, the report provides detailed initiatives that are being taken in the field of Venous Stents, globally. The report provide a detailed analysis of regions including North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), and the Rest of the World. North America dominated the market in 2020, with --% share. Boston Scientific Corporation, Medtronic Plc, Becton, Dickinson and Company, Medica Germany GMBH & Co. KG, Cook Medical, W. L. Gore & Associates, Inc. , Cordis, Jotec GmBH, Abbott Laboratories, and Optimed Medizinische Instrumente GmBH are some of the prominent players operating in the global Venous Stents market. Several M&As along with partnerships have been undertaken by these players to make Venous Stentss as cost-effective and as widely available as possible.
Venous Stents Market Segmentation
Market Insight, by Technology
- Iliac Vein Stent Technology
- Wallstent Technology
Market Insight, by Application
Market Insight, by Disease
- Chronic Deep Vein Thrombosis
- Post Thrombotic Syndrome
Market Insight, by Region
- North America Venous Stents Market
- United States
- Rest of North America
- Europe Venous Stents Market
- United Kingdom
- Rest of Europe
- Asia-Pacific Venous Stents Market
- Rest of Asia-Pacific
- Rest of World Venous Stents Market
Top Company Profiles
- Boston Scientific Corporation
- Medtronic Plc
- Becton, Dickinson and Company
- Medica Germany GMBH & Co. KG
- Cook Medical
- W. L. Gore & Associates, Inc.
- Jotec GmBH
- Abbott Laboratories
- Optimed Medizinische Instrumente GmBH
- Table Of Content:
- 1 MARKET INTRODUCTION
- 2 RESEARCH METHODOLOGY OR ASSUMPTION
- 3 MARKET SYNOPSIS
- 4 EXECUTIVE SUMMARY
- 5 COVID-19 IMPACT
- 6 MARKET INSIGHTS BY TECHNOLOGY
- 7 MARKET INSIGHTS BY APPLICATION
- 8 MARKET INSIGHTS BY DISEASE
- 9 MARKET INSIGHTS BY REGION
- 10 LEGAL AND REGULATORY FRAMEWORK
- 11 DEMAND AND SUPPLY SIDE ANALYSIS
- 12 VALUE CHAIN ANALYSIS
- 13 VENOUS STENTS MARKET TRENDS & INSIGHTS
- 14 VENOUS STENTS MARKET DYNAMICS
- 15 COMPETITIVE SCENARIO
- 16 COMPANY PROFILED
- 17 DISCLAIMER